The P72R Polymorphism of p53 Predisposes to Obesity and Metabolic Dysfunction

Cell Reports

Volumn 14, Issue 10, 2016, Pages 2413-2425

  Kung, Che Pei ^a   Leu, Julia I Ju ^b   Basu, Subhasree ^a   Khaku, Sakina ^a   Anokye Danso, Frederick ^b   Liu, Qin ^a   George, Donna L ^b   Ahima, Rexford S ^b   Murphy, Maureen E ^a  

^a WISTAR INSTITUTE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Ccl2; Diabetes; Inflammation; Islet hypertrophy; Lipid metabolism; NAFLD; Npc1l1; Obesity; P53; Pck1; Tnf

Indexed keywords

ARGININE; PROLINE; PROTEIN P53; PROTEIN VARIANT; TUMOR NECROSIS FACTOR; CARRIER PROTEIN; DRAM-1 PROTEIN, MOUSE; MEMBRANE PROTEIN; NPC1L1 PROTEIN, MOUSE; PROTEIN MDM2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOLOGICAL MONITORING; CELL INFILTRATION; CODON; CONTROLLED STUDY; DISEASE PREDISPOSITION; DISEASE SEVERITY; DNA POLYMORPHISM; FATTY LIVER; GENE; GENE EXPRESSION; GENE TARGETING; GENETIC VARIABILITY; GLUCOSE INTOLERANCE; HYPERTROPHY; IMMUNOCOMPETENT CELL; INSULIN RESISTANCE; LIPID DIET; MALE; METABOLIC DISORDER; MOLECULAR PATHOLOGY; MOUSE; NONHUMAN; NPC1 1 GENE; OBESITY; PANCREAS ISLET CELL; PHENOTYPE; PRIORITY JOURNAL; TNF GENE; ANIMAL; ANIMAL MODEL; ANTAGONISTS AND INHIBITORS; BODY WEIGHT; C57BL MOUSE; CHEMISTRY; GENETIC PREDISPOSITION; GENETICS; GLUCOSE TOLERANCE TEST; HUMAN; LIVER; METABOLISM; PANCREAS; PATHOLOGY; PATHOPHYSIOLOGY; SINGLE NUCLEOTIDE POLYMORPHISM;

ANIMALS; BODY WEIGHT; DIET, HIGH-FAT; GENETIC PREDISPOSITION TO DISEASE; GLUCOSE TOLERANCE TEST; HUMANS; INSULIN RESISTANCE; LIVER; MALE; MEMBRANE PROTEINS; MEMBRANE TRANSPORT PROTEINS; MICE; MICE, INBRED C57BL; MODELS, ANIMAL; OBESITY; PANCREAS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR NECROSIS FACTOR-ALPHA; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84960387270     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2016.02.037     Document Type: Article

References (59)

1. Abecasis G.R., Auton A., Brooks L.D., DePristo M.A., Durbin R.M., Handsaker R.E., Kang H.M., Marth G.T., McVean G.A. An integrated map of genetic variation from 1,092 human genomes. Nature 2012, 491:56-65. 1000 Genomes Project Consortium.
2. Antohe J.L., Bili A., Sartorius J.A., Kirchner H.L., Morris S.J., Dancea S., Wasko M.C. Diabetes mellitus risk in rheumatoid arthritis: reduced incidence with anti-tumor necrosis factor α therapy. Arthritis Care Res. (Hoboken) 2012, 64:215-221.
3. Aravinthan A., Scarpini C., Tachtatzis P., Verma S., Penrhyn-Lowe S., Harvey R., Davies S.E., Allison M., Coleman N., Alexander G. Hepatocyte senescence predicts progression in non-alcohol-related fatty liver disease. J. Hepatol. 2013, 58:549-556.
4. Azzam G., Wang X., Bell D., Murphy M.E. CSF1 is a novel p53 target gene whose protein product functions in a feed-forward manner to suppress apoptosis and enhance p53-mediated growth arrest. PLoS ONE 2013, 8:e74297.
5. Bechmann L.P., Gieseler R.K., Sowa J.P., Kahraman A., Erhard J., Wedemeyer I., Emons B., Jochum C., Feldkamp T., Gerken G., Canbay A. Apoptosis is associated with CD36/fatty acid translocase upregulation in non-alcoholic steatohepatitis. Liver Int. 2010, 30:850-859.
6. Beckman G., Birgander R., Själander A., Saha N., Holmberg P.A., Kivelä A., Beckman L. Is p53 polymorphism maintained by natural selection?. Hum. Hered. 1994, 44:266-270.
7. Bergamaschi D., Samuels Y., Sullivan A., Zvelebil M., Breyssens H., Bisso A., Del Sal G., Syed N., Smith P., Gasco M., et al. iASPP preferentially binds p53 proline-rich region and modulates apoptotic function of codon 72-polymorphic p53. Nat. Genet. 2006, 38:1133-1141.
8. Burgdorf K.S., Grarup N., Justesen J.M., Harder M.N., Witte D.R., Jørgensen T., Sandbæk A., Lauritzen T., Madsbad S., Hansen T., Pedersen O. Studies of the association of Arg72Pro of tumor suppressor protein p53 with type 2 diabetes in a combined analysis of 55,521 Europeans. PLoS ONE 2011, 6:e15813. DIAGRAM Consortium.
9. Carr R.M., Dhir R., Yin X., Agarwal B., Ahima R.S. Temporal effects of ethanol consumption on energy homeostasis, hepatic steatosis, and insulin sensitivity in mice. Alcohol. Clin. Exp. Res. 2013, 37:1091-1099.
10. Chang J.R., Ghafouri M., Mukerjee R., Bagashev A., Chabrashvili T., Sawaya B.E. Role of p53 in neurodegenerative diseases. Neurodegener. Dis. 2012, 9:68-80.
11. Chen Y., Shen Z. Gene polymorphisms in the folate metabolism and their association with MTX-related adverse events in the treatment of ALL. Tumour Biol. 2015, 36:4913-4921.
12. Danilova N., Sakamoto K.M., Lin S. p53 family in development. Mech. Dev. 2008, 125:919-931.
13. De Iuliis F., Salerno G., Taglieri L., Scarpa S. Are pharmacogenomic biomarkers an effective tool to predict taxane toxicity and outcome in breast cancer patients? Literature review. Cancer Chemother. Pharmacol. 2015, 76:679-690.
14. Dumont P., Leu J.I., Della Pietra A.C., George D.L., Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat. Genet. 2003, 33:357-365.
15. Firneisz G. Non-alcoholic fatty liver disease and type 2 diabetes mellitus: the liver disease of our age?. World J. Gastroenterol. 2014, 20:9072-9089.
16. Frank A.K., Leu J.I., Zhou Y., Devarajan K., Nedelko T., Klein-Szanto A., Hollstein M., Murphy M.E. The codon 72 polymorphism of p53 regulates interaction with NF-kappaB and transactivation of genes involved in immunity and inflammation. Mol. Cell. Biol. 2011, 31:1201-1213.
17. Gaulton K.J., Willer C.J., Li Y., Scott L.J., Conneely K.N., Jackson A.U., Duren W.L., Chines P.S., Narisu N., Bonnycastle L.L., et al. Comprehensive association study of type 2 diabetes and related quantitative traits with 222 candidate genes. Diabetes 2008, 57:3136-3144.
18. Gloria-Bottini F., Banci M., Saccucci P., Magrini A., Bottini E. Is there a role of p53 codon 72 polymorphism in the susceptibility to type 2 diabetes in overweight subjects? A study in patients with cardiovascular diseases. Diabetes Res. Clin. Pract. 2011, 91:e64-e67.
19. Goldstein I., Rotter V. Regulation of lipid metabolism by p53 - fighting two villains with one sword. Trends Endocrinol. Metab. 2012, 23:567-575.
20. Gruben N., Shiri-Sverdlov R., Koonen D.P., Hofker M.H. Nonalcoholic fatty liver disease: A main driver of insulin resistance or a dangerous liaison?. Biochim. Biophys. Acta 2014, 1842:2329-2343.
21. Hacke K., Rincon-Orozco B., Buchwalter G., Siehler S.Y., Wasylyk B., Wiesmüller L., Rösl F. Regulation of MCP-1 chemokine transcription by p53. Mol. Cancer 2010, 9:82.
22. Haukeland J.W., Damås J.K., Konopski Z., Løberg E.M., Haaland T., Goverud I., Torjesen P.A., Birkeland K., Bjøro K., Aukrust P. Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2. J. Hepatol. 2006, 44:1167-1174.
23. Kang H.J., Feng Z., Sun Y., Atwal G., Murphy M.E., Rebbeck T.R., Rosenwaks Z., Levine A.J., Hu W. Single-nucleotide polymorphisms in the p53 pathway regulate fertility in humans. Proc. Natl. Acad. Sci. USA 2009, 106:9761-9766.
24. Khan M.M., Rydén A.M., Chowdhury M.S., Hasan M.A., Kazi J.U. Maximum likelihood analysis of mammalian p53 indicates the presence of positively selected sites and higher tumorigenic mutations in purifying sites. Gene 2011, 483:29-35.
25. Kung C.P., Khaku S., Jennis M., Zhou Y., Murphy M.E. Identification of TRIML2, a novel p53 target, that enhances p53 SUMOylation and regulates the transactivation of proapoptotic genes. Mol. Cancer Res. 2015, 13:250-262.
26. Levine A.J., Oren M. The first 30 years of p53: growing ever more complex. Nat. Rev. Cancer 2009, 9:749-758.
27. Levine A.J., Tomasini R., McKeon F.D., Mak T.W., Melino G. The p53 family: guardians of maternal reproduction. Nat. Rev. Mol. Cell Biol. 2011, 12:259-265.
28. Li T., Kon N., Jiang L., Tan M., Ludwig T., Zhao Y., Baer R., Gu W. Tumor suppression in the absence of p53-mediated cell-cycle arrest, apoptosis, and senescence. Cell 2012, 149:1269-1283.
29. Liang Y., Liu J., Feng Z. The regulation of cellular metabolism by tumor suppressor p53. Cell Biosci. 2013, 3:9.
30. Long J.S., Crighton D., O'Prey J., Mackay G., Zheng L., Palmer T.M., Gottlieb E., Ryan K.M. Extracellular adenosine sensing-a metabolic cell death priming mechanism downstream of p53. Mol. Cell 2013, 50:394-406.
31. Luo J.L., Yang Q., Tong W.M., Hergenhahn M., Wang Z.Q., Hollstein M. Knock-in mice with a chimeric human/murine p53 gene develop normally and show wild-type p53 responses to DNA damaging agents: a new biomedical research tool. Oncogene 2001, 20:320-328.
32. Maddocks O.D., Berkers C.R., Mason S.M., Zheng L., Blyth K., Gottlieb E., Vousden K.H. Serine starvation induces stress and p53-dependent metabolic remodelling in cancer cells. Nature 2013, 493:542-546.
33. Menendez D., Shatz M., Resnick M.A. Interactions between the tumor suppressor p53 and immune responses. Curr. Opin. Oncol. 2013, 25:85-92.
34. Minamino T., Orimo M., Shimizu I., Kunieda T., Yokoyama M., Ito T., Nojima A., Nabetani A., Oike Y., Matsubara H., et al. A crucial role for adipose tissue p53 in the regulation of insulin resistance. Nat. Med. 2009, 15:1082-1087.
35. Molchadsky A., Ezra O., Amendola P.G., Krantz D., Kogan-Sakin I., Buganim Y., Rivlin N., Goldfinger N., Folgiero V., Falcioni R., et al. p53 is required for brown adipogenic differentiation and has a protective role against diet-induced obesity. Cell Death Differ. 2013, 20:774-783.
36. Nomura M., Ishii H., Kawakami A., Yoshida M. Inhibition of hepatic Niemann-Pick C1-like 1 improves hepatic insulin resistance. Am. J. Physiol. Endocrinol. Metab. 2009, 297:E1030-E1038.
37. Ortega F.J., Moreno-Navarrete J.M., Mayas D., Serino M., Rodriguez-Hermosa J.I., Ricart W., Luche E., Burcelin R., Tinahones F.J., Frühbeck G., et al. Inflammation and insulin resistance exert dual effects on adipose tissue tumor protein 53 expression. Int. J. Obes. 2014, 38:737-745.
38. Ota T. Chemokine systems link obesity to insulin resistance. Diabetes Metab. J. 2013, 37:165-172.
39. Park S.W. Intestinal and hepatic niemann-pick c1-like 1. Diabetes Metab. J. 2013, 37:240-248.
40. Park J., Morley T.S., Kim M., Clegg D.J., Scherer P.E. Obesity and cancer--mechanisms underlying tumour progression and recurrence. Nat. Rev. Endocrinol. 2014, 10:455-465.
41. Pim D., Banks L. p53 polymorphic variants at codon 72 exert different effects on cell cycle progression. Int. J. Cancer 2004, 108:196-199.
42. Poyurovsky M.V., Prives C. P53 and aging: A fresh look at an old paradigm. Aging (Albany, N.Y.) 2010, 2:380-382.
43. Puente X.S., Velasco G., Gutiérrez-Fernández A., Bertranpetit J., King M.C., López-Otín C. Comparative analysis of cancer genes in the human and chimpanzee genomes. BMC Genomics 2006, 7:15.
44. Reiling E., Lyssenko V., Boer J.M., Imholz S., Verschuren W.M., Isomaa B., Tuomi T., Groop L., Dollé M.E. Codon 72 polymorphism (rs1042522) of TP53 is associated with changes in diastolic blood pressure over time. Eur. J. Hum. Genet. 2012, 20:696-700.
45. Reiling E., Speksnijder E.N., Pronk A.C., van den Berg S.A., Neggers S.J., Rietbroek I., van Steeg H., Dollé M.E. Human TP53 polymorphism (rs1042522) modelled in mouse does not affect glucose metabolism and body composition. Sci. Rep. 2014, 4:4091.
46. Sano M., Minamino T., Toko H., Miyauchi H., Orimo M., Qin Y., Akazawa H., Tateno K., Kayama Y., Harada M., et al. p53-induced inhibition of Hif-1 causes cardiac dysfunction during pressure overload. Nature 2007, 446:444-448.
47. Sellayah D., Cagampang F.R., Cox R.D. On the evolutionary origins of obesity: a new hypothesis. Endocrinology 2014, 155:1573-1588.
48. She P., Shiota M., Shelton K.D., Chalkley R., Postic C., Magnuson M.A. Phosphoenolpyruvate carboxykinase is necessary for the integration of hepatic energy metabolism. Mol. Cell. Biol. 2000, 20:6508-6517.
49. Shi H., Tan S.J., Zhong H., Hu W., Levine A., Xiao C.J., Peng Y., Qi X.B., Shou W.H., Ma R.L., et al. Winter temperature and UV are tightly linked to genetic changes in the p53 tumor suppressor pathway in Eastern Asia. Am. J. Hum. Genet. 2009, 84:534-541.
50. Speliotes E.K., Willer C.J., Berndt S.I., Monda K.L., Thorleifsson G., Jackson A.U., Lango Allen H., Lindgren C.M., Luan J., Mägi R., et al. Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat. Genet. 2010, 42:937-948. MAGIC, Procardis ConsortiumProcardis Consortium.
51. Stienstra R., van Diepen J.A., Tack C.J., Zaki M.H., van de Veerdonk F.L., Perera D., Neale G.A., Hooiveld G.J., Hijmans A., Vroegrijk I., et al. Inflammasome is a central player in the induction of obesity and insulin resistance. Proc. Natl. Acad. Sci. USA 2011, 108:15324-15329.
52. Sucheston L., Witonsky D.B., Hastings D., Yildiz O., Clark V.J., Di Rienzo A., Onel K. Natural selection and functional genetic variation in the p53 pathway. Hum. Mol. Genet. 2011, 20:1502-1508.
53. Tavana O., Puebla-Osorio N., Sang M., Zhu C. Absence of p53-dependent apoptosis combined with nonhomologous end-joining deficiency leads to a severe diabetic phenotype in mice. Diabetes 2010, 59:135-142.
54. Thomas M., Kalita A., Labrecque S., Pim D., Banks L., Matlashewski G. Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol. Cell. Biol. 1999, 19:1092-1100.
55. Tomita K., Teratani T., Suzuki T., Oshikawa T., Yokoyama H., Shimamura K., Nishiyama K., Mataki N., Irie R., Minamino T., et al. p53/p66Shc-mediated signaling contributes to the progression of non-alcoholic steatohepatitis in humans and mice. J. Hepatol. 2012, 57:837-843.
56. Vousden K.H., Ryan K.M. p53 and metabolism. Nat. Rev. Cancer 2009, 9:691-700.
57. Wang Y., Rimm E.B., Stampfer M.J., Willett W.C., Hu F.B. Comparison of abdominal adiposity and overall obesity in predicting risk of type 2 diabetes among men. Am. J. Clin. Nutr. 2005, 81:555-563.
58. Whibley C., Pharoah P.D., Hollstein M. p53 polymorphisms: cancer implications. Nat. Rev. Cancer 2009, 9:95-107.
59. Zhang P., Tu B., Wang H., Cao Z., Tang M., Zhang C., Gu B., Li Z., Wang L., Yang Y., et al. Tumor suppressor p53 cooperates with SIRT6 to regulate gluconeogenesis by promoting FoxO1 nuclear exclusion. Proc. Natl. Acad. Sci. USA 2014, 111:10684-10689.